Current Price $43.09 NYSE: BMY Bristol Myers Squibb Market Cap $95B Current Price $46.89 Premium Investing Services Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. ...
Check the Lilly(Eli) & Co stock price today on the NYSE stock exchange and access historical LLY stock price chart. Get the latest Lilly(Eli) & Co stock information.
What is Eli Lilly and Company's stock price today? Eli Lilly and Company is currently listed on NYSE under LLY. One share of LLY stock can currently be purchased for approximately $885.20. Eli Lilly and Company’s current P/E Non-GAAP (TTM) sector relative grade is F. With Seeking Alph...
Kate Stalter andAaron Davis May 2, 2025 Investing 9 of the Best Bond ETFs to Buy for 2025 Modern bond ETFs can provide exposure to specialized, hard-to-access segments of the fixed-income market. Tony Dong andJohn Divine May 2, 2025 ...
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report ...
TheMotley Fool Stock Advisoranalyst team just identified what they believe are the10 best stocksfor investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. ...
Originally, analysts had expected LLY to price Elanco stock between $20 and $23 per share, but the company surprised Wall Street by pricing the stock at $24. Shares then opened at $32.25 on Sept. 20 when trading began. This means that LLY received more than many were expecting for the ...
Price Performance Comparison Over the last year, Eli Lilly’s stock is up a very respectable 25% which has roughly matched the S&P 500 while Novo Nordisk shares are down a lackluster -21%. Notably, the dip in Novo Nordisk’s stock has been attributed to subpar clinical trial results for ...
Price Performance Comparison Over the last year, Eli Lilly’s stock is up a very respectable 25% which has roughly matched the S&P 500 while Novo Nordisk shares are down a lackluster -21%. Notably, the dip in Novo Nordisk’s stock has been attributed to subpar clinical trial results for ...
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. ...